13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurology and Systemic Disorders
The intersection of neurology and systemic disorders offers a deeper understanding of how diseases affecting the entire body, such as diabetes, thyroid disorders, and infections, can manifest with neurological symptoms. Systemic conditions often exacerbate neurological disorders, leading to increased morbidity and more complex treatment challenges. Research into the pathophysiology of these interactions is revealing how factors like immune response, metabolic imbalances, and cardiovascular health contribute to neurological dysfunction. For example, uncontrolled diabetes can lead to diabetic neuropathy, while hypertension is a major risk factor for stroke. By advancing knowledge in both neurology and systemic diseases, clinicians are better equipped to provide comprehensive care that addresses both the neurological and systemic aspects of these conditions, enhancing patient management and quality of life.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States